Youssef Hanna, MD
Hematology & Oncology · Port Huron, MINPI 1639115397
Payments from drug & device makers
Across 195 payments — averaging $74.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$10K
- Novartis$717
- Johnson & Johnson$451
- AstraZeneca$320
- E.r. Squibb & Sons, L.L.C.$279
- AbbVie$259
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,15393%
- Education$3237%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $10,310 |
| Novartis | 39 | $717 |
| Johnson & Johnson(3 entities) | 15 | $451 |
| AstraZeneca | 11 | $320 |
| E.r. Squibb & Sons, L.L.C. | 5 | $279 |
| AbbVie | 7 | $259 |
| Exelixis Inc. | 4 | $203 |
| Amgen | 6 | $183 |
| GSK | 8 | $164 |
| AMAG Pharmaceuticals, Inc. | 7 | $142 |
| Gilead(2 entities) | 7 | $127 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Array Biopharma Inc | 6 | $116 |
| Merck | 6 | $99 |
| Mirati Therapeutics, Inc. | 5 | $92 |
| Seagen Inc. | 6 | $89 |
| Genentech USA, Inc. | 2 | $77 |
| Sanofi | 3 | $72 |
| Bristol Myers Squibb | 4 | $62 |
| Incyte Corporation | 1 | $59 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $47 |
| Deciphera Pharmaceuticals Inc. | 3 | $47 |
| AVEO Pharmaceuticals, Inc. | 3 | $45 |
| EMD Serono, Inc. | 1 | $44 |
| Servier Pharmaceuticals LLC | 2 | $41 |
| Medtronic | 1 | $37 |
| Puma Biotechnology, Inc. | 2 | $34 |
| Tesaro, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Eisai Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,477 in reported general payments places this provider in the 70th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 63 | $836,692 |
| RevlimidLenalidomide | 45 | $814,547 |
| PomalystPomalidomide | 29 | $667,379 |
| IbrancePalbociclib | 38 | $612,719 |
| VerzenioAbemaciclib | 25 | $398,455 |
| TagrissoOsimertinib Mesylate | 23 | $382,394 |
| TibsovoIvosidenib | 12 | $382,181 |
| TasignaNilotinib Hcl | 12 | $228,931 |
| ImbruvicaIbrutinib | 14 | $219,470 |
| BosulifBosutinib | 14 | $216,909 |
| MekinistTrametinib Dimethyl Sulfoxide | 14 | $205,755 |
| TafinlarDabrafenib Mesylate | 14 | $189,509 |
| VenclextaVenetoclax | 20 | $179,548 |
| PegasysPeginterferon Alfa-2a | 33 | $145,233 |
| NubeqaDarolutamide | 11 | $143,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Bosulif, Eliquis | $10,310 | $887,35094 claims |
| Bristol Myers SquibbRevlimid | $62 | $814,54745 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Reblozyl | $279 | $802,83843 claims |
| NovartisTasigna, Mekinist, Tafinlar | $717 | $624,19540 claims |
| AstraZenecaTagrisso | $320 | $382,39423 claims |
| Servier Pharmaceuticals LLCTibsovo | $41 | $382,18112 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $47 | $219,47014 claims |
| AbbVieVenclexta | $259 | $179,54820 claims |
| Johnson & JohnsonXarelto, Procrit | $451 | $148,17784 claims |
| GSKBreo Ellipta | $164 | $4,32411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Port Huron
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Assuntina SaccoAnn Arbor$8.1M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
- Igor RybkinDetroit$2.4M
- Jason BrownAnn Arbor$2.3M
- Brett BrinkerGrand Rapids$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.